MARINE NATURAL PRODUCTS AS ANTI-ANGIOGENIC AND ANTI-INVASIVE AGENTS
海洋天然产品作为抗血管生成和抗侵袭剂
基本信息
- 批准号:7609940
- 负责人:
- 金额:$ 13.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-05-01 至 2008-04-30
- 项目状态:已结题
- 来源:
- 关键词:Actinobacteria classActinomycesCallyspongiaCause of DeathClassComputer Retrieval of Information on Scientific Projects DatabaseEvaluationFundingFutureGenesGoalsGrantHydantoinsIndolesInstitutionInvasiveMalignant NeoplasmsMarine InvertebratesMarinesMediatingMethodsPhenazinesPoriferaReactionRecombinant DNARed SeaResearchResearch PersonnelResourcesRibosomal DNASourceTestingUnited States National Institutes of Healthanaloganticancer activitycoraldesigndiketopiperazineindolemarine natural productmicroorganismnovelprototypesarcophinesmall molecule
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Cancer remains one of the major global causes of death. Marine natural products are enormous resource of diverse, unique, and highly bioactive compounds. The ultimate goal of this study is to discover and optimize prototype antiproliferative, antimetastatic, anti-migratory, and antiinvasive leads of marine origin. Our research is focused on four different classes of readily available marine-derived secondary metabolites and their analogs. These compounds are common in the Red Sea marine sponges Negombata magnifica, Callyspongia siphonella, Hemimycale arabica, and the soft coral Sarcophyton glaucum. We hypothesized that effective prototypic anticancer latrunculins, sipholanes, hydantoins, and sarcophines can be generated and optimized using biocatalysis and rational semisynthetic approaches. Many bioactive compounds isolated from marine invertebrates are originating from symbiotic microorganisms. We also hypothesized that symbiotic microorganisms associated with the Red Sea sponges N. magnifica, and C. siphonella can be used as a source of novel anticancer entities.
The specific aims of this study were: 1) optimization of latrunculins, sipholanes, hydantoins, and cembranoids using biocatalytic and rational semisynthetic reactions; 2) isolation and identification of symbiotic microorganisms associated with N. magnifica, and C. siphonella; 3) large-scale culturing of the isolated microorganisms and testing their extracts for novel secondary metabolites; and 4) evaluation of anticancer activities of the isolated compounds.
Several new bioconversion and semisynthetic products of sarcophine, 2-epi-16-deoxysarcophine, latrunculins A and B, sipholenol A, and sipholenone A were generated and identified using spectral methods. More than 100 bacterial and actinomycete species were cultured and identified using 16S rDNA gene sequencing. Novel diketopiperazine, indole, and
phenazine analogs were isolated from Kocuria, Pontibacillus, and Pelagiobacter species, respectively. Some of these compounds showed potent anticancer activities including antiinvasive, anti-migratory, anti-angiogenic, antiproliferative, HIF-1, and P-gp-mediated MDR inhibitory activities. Future efforts will be focused on the discovery and design of bioisosteric small molecules that can serve as prototype anticancer leads.
这个子项目是许多研究子项目中的一个
由NIH/NCRR资助的中心赠款提供的资源。子项目和
研究者(PI)可能从另一个NIH来源获得了主要资金,
因此可以在其他CRISP条目中表示。所列机构为
研究中心,而研究中心不一定是研究者所在的机构。
癌症仍然是全球主要的死亡原因之一。海洋天然产物是一种丰富多样、独特独特的高生物活性化合物资源。本研究的最终目标是发现和优化原型抗增殖,抗转移,抗迁移和抗侵入的海洋来源的铅。我们的研究集中在四个不同类别的现成的海洋衍生的次级代谢产物及其类似物。这些化合物在红海海绵Negombata magnifica、Callysongia siphonella、Hemimycale arabica和软珊瑚Sarcophyton glaucum中很常见。我们假设,有效的原型抗癌latrunculins,sipholanes,乙内酰脲,和sarcophines可以产生和优化使用生物催化和合理的半合成方法。从海洋无脊椎动物中分离出的许多生物活性化合物来源于共生微生物。我们还假设与红海海绵N. magnifica和C.管胞菌可用作新抗癌实体的来源。
本研究的具体目的是:1)利用生物催化和合理的半合成反应优化latrunculins,sipholanes,hetoins和cesbranoids; 2)分离和鉴定与N. magnifica和C.虹吸管; 3)大规模培养分离的微生物并测试其提取物的新次级代谢产物;和4)评价分离的化合物的抗癌活性。
利用光谱分析方法,合成并鉴定了几种新的sarcophine生物转化和半合成产物:2-epi-16-deoxysarcophine、latrunculins A和B、sipholenol A和sipholenone A。100多种细菌和放线菌的培养和鉴定使用16 S rDNA基因测序。新的二酮哌嗪,吲哚,和
吩嗪类似物分别从库克菌属(Kocuria)、庞蒂芽孢杆菌属(Pontibacillus)和Pelagiacillus物种中分离。这些化合物中的一些显示出有效的抗癌活性,包括抗侵袭、抗迁移、抗血管生成、抗增殖、HIF-1和P-gp介导的MDR抑制活性。未来的努力将集中在发现和设计生物电子等排小分子,可以作为原型抗癌线索。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KHALID A EL SAYED其他文献
KHALID A EL SAYED的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KHALID A EL SAYED', 18)}}的其他基金
Targeting PCSK9 axis for castration-resistant prostate cancer recurrence suppression
靶向 PCSK9 轴抑制去势抵抗性前列腺癌复发
- 批准号:
10555260 - 财政年份:2022
- 资助金额:
$ 13.87万 - 项目类别:
Targeting PCSK9 axis for castration-resistant prostate cancer recurrence suppression
靶向 PCSK9 轴抑制去势抵抗性前列腺癌复发
- 批准号:
10429627 - 财政年份:2022
- 资助金额:
$ 13.87万 - 项目类别:
Oleocanthal functional food products for breast cancer recurrence control
用于控制乳腺癌复发的油橄榄功能性食品
- 批准号:
10276305 - 财政年份:2020
- 资助金额:
$ 13.87万 - 项目类别:
Design of novel c-Met inhibitors inspired by olive phenolics
受橄榄酚类启发的新型 c-Met 抑制剂的设计
- 批准号:
8434417 - 财政年份:2013
- 资助金额:
$ 13.87万 - 项目类别:
MARINE NATURAL PRODUCTS AS ANTI-ANGIOGENIC AND ANTI-INVASIVE AGENTS
海洋天然产品作为抗血管生成和抗侵袭剂
- 批准号:
7959461 - 财政年份:2009
- 资助金额:
$ 13.87万 - 项目类别:
MARINE NATURAL PRODUCTS AS ANTI-ANGIOGENIC AND ANTI-INVASIVE AGENTS
海洋天然产品作为抗血管生成和抗侵袭剂
- 批准号:
7719997 - 财政年份:2008
- 资助金额:
$ 13.87万 - 项目类别:
DEVELOPMENT OF MARINE MACROLIDES LATRUNCULINS AS ANGIOGENESIS MODULATORS
作为血管生成调节剂的海洋大环内酯 Latrunculins 的开发
- 批准号:
7381335 - 财政年份:2006
- 资助金额:
$ 13.87万 - 项目类别:
ANTICANCER AND ANTI-INFECTIVE METABILITES FOR SYMBIOTIC MARINE MICROORGANISMS
共生海洋微生物的抗癌和抗感染代谢物
- 批准号:
7381336 - 财政年份:2006
- 资助金额:
$ 13.87万 - 项目类别:
DEVELOPMENT OF THE MARINE MACROLIDES LATRUNCULINS
海洋大环内酯类 LATRUNCULINS 的开发
- 批准号:
6981539 - 财政年份:2003
- 资助金额:
$ 13.87万 - 项目类别:
相似海外基金
Development of anti-scirrhous stomach cancer produced by the deep-sea actinomyces
深海放线菌抗硬胃癌的开发
- 批准号:
21H03007 - 财政年份:2021
- 资助金额:
$ 13.87万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Comprehensive analysis of the fluoride-effects on the metabolic mechanism of oral Actinomyces
氟对口腔放线菌代谢机制影响的综合分析
- 批准号:
16K20447 - 财政年份:2016
- 资助金额:
$ 13.87万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Breakthrough of fluoride-functional mechanism and establishment of its utilization for oral Actinomyces
氟作用机制的突破及其在口腔放线菌中的应用
- 批准号:
25861783 - 财政年份:2013
- 资助金额:
$ 13.87万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
The role of the initial colonizer Actinomyces oris in dental plaque formation.
初始定殖者口放线菌在牙菌斑形成中的作用。
- 批准号:
24592790 - 财政年份:2012
- 资助金额:
$ 13.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genome sequencing and mutational analysis of the Actinomyces strains with enhanced biofilm phenotype
具有增强生物膜表型的放线菌菌株的基因组测序和突变分析
- 批准号:
23792118 - 财政年份:2011
- 资助金额:
$ 13.87万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Molecular Assembly on the Cell Surface of Actinomyces
放线菌细胞表面的分子组装
- 批准号:
8774895 - 财政年份:2008
- 资助金额:
$ 13.87万 - 项目类别:
Molecular Assembly on the Cell Surface of Actinomyces
放线菌细胞表面的分子组装
- 批准号:
8588304 - 财政年份:2008
- 资助金额:
$ 13.87万 - 项目类别:
Molecular Assembly on the Cell Surface of Actinomyces
放线菌细胞表面的分子组装
- 批准号:
10455056 - 财政年份:2008
- 资助金额:
$ 13.87万 - 项目类别:
Molecular Assembly on the Cell Surface of Actinomyces
放线菌细胞表面的分子组装
- 批准号:
7783826 - 财政年份:2008
- 资助金额:
$ 13.87万 - 项目类别:
Molecular Assembly on the Cell Surface of Actinomyces
放线菌细胞表面的分子组装
- 批准号:
7373000 - 财政年份:2008
- 资助金额:
$ 13.87万 - 项目类别:














{{item.name}}会员




